Skip to content
University of Colorado Anschutz Medical Campus CU Anschutz
  • Webmail
  • UCD Access
  • Canvas
  • Quick Links
 

Tools & Resources

  • Events Calendar
  • Newsroom
  • Strauss Health Sciences Library
  • Department A-Z Directory
  • Campus Directory
  • Leadership
  • Faculty & Staff Resources
  • Supporter & Alumni Resources
  • Student Resources
  • Campus Map
  • University Policies
  • Give Now

CU Campuses

  • CU Anschutz Medical Campus
  • CU Boulder
  • CU Colorado Springs
  • CU Denver
  • CU System
  • CU Online

CU Anschutz Medical Campus

  • School of Dental Medicine
  • Graduate School
  • School of Medicine
  • College of Nursing
  • Skaggs School of Pharmacy and Pharmaceutical Sciences
  • Colorado School of Public Health

Division of Medical Oncology

School of Medicine

  • Home
  • Leadership
    • Division Head | Wells Messersmith, MD, FACP
    • Deputy Division Head | Virginia Borges, MD, MMSc
  • Research
  • Cancer Care
    • CARE Clinic
    • Clinical Trials
    • Find a Provider
    • Satellite Locations
  • Education
  • Giving
  • Newsroom
  • Division Resources
  • Division Directory
    • Clinical & Research Faculty
    • Research Services Personnel
    • Administrative Staff
University Quick Links
  • Home
  • Newsroom

Medical Oncology Newsroom

What is Fibrolamellar Hepatocellular Carcinoma (HCC)?

Oct 8, 2021
  Fibrolamellar hepatocellular carcinoma (HCC) tumors are so rare, that they are typically found by surprise.  Because Fibrolamellar HCC is so rare, making up 1% or less of all liver cancers there is very little data on treatment.  While HCCs, by and large, are an adult cancer that tend to occur in older patients who have underlying liver diseases Dr. Alexis Leal says "fibrolamellar HCC, in stark contrast, is a disease of children, adolescents, and young adults who don't have liver disease."

According to Dr. Leal symptoms of fibrolamellar HCC Include: 
  • Pain or a feeling of fullness in the abdomen, shoulder, or back, specifically in the upper right abdomen
  • Nausea and vomiting
  • Loss of appetite
  • Unexplained weight loss
  • Malaise, having less energy or generally feeling unwell
  • Jaundice
  • A palpable mass in the upper abdomen
The high rate of recurrence associated with fibrolamellar HCC following immunotherapy and chemotherapy treatments means that patients must be closely monitored for at least five years.  This includes scans and physical exams that will allow physicians to watch for any sign of the cancer returning. 

“I’ve taken care of so many patients, and I think that that kind of good attitude goes a long way.  There’s something to be said for having a positive outlook and rolling with the ups and the downs that can come with treatment. I’ve seen a number of patients who have that attitude, and I do feel like it tends to have a positive impact on their treatment and on those around them.” says Dr. Leal.

 YOU MAY ALSO LIKE

CU ANSCHUTZ NEWS

CU CANCER CENTER NEWS

DIVISION OF HEMATOLOGY

UCHEALTH TODAY

Medical Oncology (SOM)

CU Anschutz

Research I South

12801 East 17th Avenue

8122

Aurora, CO 80045


720-848-0300

Facebook Twitter
School
  • School of Medicine Home
  • Find a Doctor
  • Find a Researcher
  • Departments
  • Contact Us
  • Donate
  • School Profiles
General
  • Affiliate/Partner Hospitals
  • CU Medicine
  • A-Z Index
  • Directory
  • Map and Parking
  • Webmail
Students
  • Apply Now
  • Alumni
  • Canvas
  • Health Science Library
  • Student Life
  • Colorado Springs Branch
  • Contact Us
  • Website Feedback
  • CU System
  • Privacy Policy
  • Terms of Use
  • Accessibility
  • Accreditation
  • Employment
  • Give Now
 

© 2023 The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.

CMS Login

Webmail

UCD Access

Canvas

Opens in a new window Opens document in a new window